Compare AUB & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUB | ACAD |
|---|---|---|
| Founded | 1902 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.4B |
| IPO Year | N/A | 2004 |
| Metric | AUB | ACAD |
|---|---|---|
| Price | $38.03 | $25.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 22 |
| Target Price | ★ $40.50 | $30.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 01-22-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | ★ 1.75 | 1.54 |
| Revenue | ★ $1,048,582,000.00 | $1,047,118,000.00 |
| Revenue This Year | $79.32 | $15.16 |
| Revenue Next Year | $14.97 | $11.79 |
| P/E Ratio | $21.87 | ★ $16.86 |
| Revenue Growth | ★ 41.48 | 12.69 |
| 52 Week Low | $22.85 | $13.40 |
| 52 Week High | $39.22 | $28.35 |
| Indicator | AUB | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 63.18 | 45.95 |
| Support Level | $36.53 | $25.90 |
| Resistance Level | $38.80 | $27.06 |
| Average True Range (ATR) | 0.87 | 0.74 |
| MACD | 0.10 | -0.21 |
| Stochastic Oscillator | 79.98 | 32.33 |
Atlantic Union Bankshares Corp is a financial holding company and a bank holding company. Through its community bank subsidiary, the company provides financial services, including banking, trust, and wealth management. The bank is a full-service community bank offering consumers and businesses a wide range of banking and related financial services, including checking, savings, certificates of deposit, and other depository services, as well as loans for commercial, industrial, residential mortgage, and consumer purposes. The company operates through two reportable operating segments: Wholesale Banking and Consumer Banking, with corporate support functions such as corporate treasury and others included in Corporate Other. It derives maximum revenue from Wholesale Banking.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.